Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2006;332:570 (11 March), doi:10.1136/bmj.332.7541.570
Zosia Kmietowicz
London
As the world's first linked newborn and antenatal screening programme for haemoglobinopathies is now being rolled out in England, Zosia Kmietowicz looks at the challenges the programme faces
| The first 150 words of the full text of this article appear below. |
By the end of this year all pregnant women in England thought to be at risk of having a child with sickle cell disease will be offered a screening test for the blood disorder. This is in addition to universal screening of pregnant women for thalassaemia.
The introduction of a national antenatal screening test for the haemoglobinopathies should mean an end to surprise diagnoses among infants presenting with severe overwhelming infections and splenic crises, said Allison Streetly, director of the NHS sickle cell and thalassaemia screening programme. "Ultimately, every baby born with one of the blood disorders should be expected and be the result of an informed choice," she said. "And appropriate and comprehensive care should be available from birth."
The antenatal screening programme for the haemoglobinopathies runs alongside the national programme for screening newborn babies for sickle cell disease. The programmes are the world's first to link results from
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
StumbleUpon
Technorati What's this?
Read all Rapid Responses